• If you are wondering whether Danaher's current share price lines up with its underlying value, you are not alone. This article is designed to help you size that up with clear numbers.
• Over the past month, the stock has seen a 6.7% decline, with a 2.2% drop over the last week and a 4.7% decline year to date, while the 1 year return stands at 4.1% and the 5 year return at 6.6%.
• These moves sit against a backdrop of ongoing interest in Danaher as a large life sciences and diagnostics group, with investors regularly reassessing how its portfolio and market position line up with its current share price. The aim here is not to react to a single headline, but to look at what the recent pricing means when you line it up with fundamentals.
• On Simply Wall St's 6 point valuation checklist, Danaher currently scores 2 out of 6. Next, we will walk through what different valuation approaches say about that score, before ending with a way to think about value that goes beyond any single metric.

Danaher scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Danaher Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes projected future cash flows and discounts them back to today to estimate what the business could be worth right now. It is essentially asking what you might pay today for the cash the company is expected to generate in the future.

For Danaher, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model based on cash flow projections. The latest twelve month Free Cash Flow is about $5.1b. Analyst estimates and extrapolated assumptions point to projected Free Cash Flow of $7.8b by 2029, with further projections out to 2035 provided by the model rather than by analysts.

After discounting all those projected cash flows back to today in dollars, the model arrives at an estimated intrinsic value of $229.37 per share. Compared with the current share price, this implies a 4.3% discount, which sits in a range where the stock can reasonably be viewed as trading close to what the DCF suggests it might be worth.

Result: ABOUT RIGHT

Danaher is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Danaher Price vs Earnings

For a profitable business like Danaher, the P/E ratio is a useful shorthand for how much you are paying for each dollar of current earnings. It links directly to what the company is actually earning today, which is often where investors start when they compare opportunities.

What counts as a “normal” P/E depends on what the market expects and how risky those expectations look. Higher expected earnings growth or lower perceived risk can support a higher P/E, while slower growth or higher risk usually lines up with a lower P/E.

Danaher currently trades on a P/E of 43.11x. That is above the Life Sciences industry average of 36.80x and above the peer group average of 30.37x. Simply Wall St’s Fair Ratio for Danaher is 32.11x. This is its proprietary view of what a balanced P/E could look like after considering factors such as earnings growth, profit margins, industry, market cap and company specific risks.

The Fair Ratio aims to go further than basic peer or industry comparisons because it adjusts for Danaher’s own profile instead of assuming that all Life Sciences companies should trade on the same multiple. With the shares at 43.11x compared to a Fair Ratio of 32.11x, the stock screens as trading at a richer multiple than that model suggests.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1432 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Danaher Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple tool that lets you write the story behind your numbers, including your view of Danaher’s fair value and its future revenue, earnings and margins.

A Narrative ties your view of the business to a financial forecast and then to a fair value, so instead of just seeing a P/E or DCF output, you see how your assumptions feed into the final number.

On Simply Wall St, within the Community page used by millions of investors, Narratives are designed to be approachable, helping you compare each Narrative’s Fair Value to the current share price so you can decide whether you see Danaher as priced above, below or close to what you think it is worth.

Narratives also update when new information such as news or earnings is added to the platform. For Danaher, you might see one Narrative that assumes a relatively low fair value and cautious margins, while another assumes higher revenue growth and a higher fair value, reflecting how different investors can look at the same company and reach very different conclusions.

Do you think there's more to the story for Danaher? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.